The Treatment of Relapsed Refractory Chronic Lymphocytic Leukemia

被引：35

作者：

Brown, Jennifer R. ^{[1
,2
]}

机构：

[1] Harvard Univ, Sch Med, Boston, MA 02215 USA

[2] Dana Farber Canc Inst, CLL Ctr, Boston, MA 02215 USA

来源：

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM | 2011年

关键词：

STEM-CELL TRANSPLANTATION; HIGH-DOSE METHYLPREDNISOLONE; TERM-FOLLOW-UP; MARROW-TRANSPLANTATION; ALEMTUZUMAB CAMPATH-1H; CLINICAL-EFFICACY; EFFECTIVE THERAPY; SALVAGE THERAPY; POOR-PROGNOSIS; FLUDARABINE;

D O I：

10.1182/asheducation-2011.1.110

中图分类号：

G40 [教育学];

学科分类号：

040101 ; 120403 ;

摘要：

Despite the widespread use of highly effective chemoimmunotherapy (CIT), fludarabine-refractory chronic lymphocytic leukemia (CLL) remains a challenging clinical problem associated with poor overall survival (OS). The traditional definition, which includes those patients with no response or relapse within 6 months of fludarabine, is evolving with the recognition that even patients with longer remissions of up to several years after CIT have poor subsequent treatment response and survival. Approved therapeutic options for these patients remain limited, and the goal of therapy for physically fit patients is often to achieve adequate cytoreduction to proceed to allogeneic stem cell transplantation (alloSCT). Fortunately, several novel targeted therapeutics in clinical trials hold promise of significant benefit for this patient population. This review discusses the activity of available and novel therapeutics in fludarabine-refractory or fludarabine-resistant CLL as well as recently updated data on alloSCT in CLL.

引用

页码：110 / 118

页数：9

共 66 条

[51] Induction Therapy with Idarubicin and Etoposide Combined with Sequential or Concurrent Azacitidine In Patients with High-Risk Acute Myeloid Leukemia: Pilot-Phase of the AMLSG 12-09 Study. [J].

Ruecker, Frank G. ;

Stilgenbauer, Stephan ;

Bommer, Martin ;

Spaeth, Daniela ;

Mack, Silja ;

Doehner, Konstanze ;

Doehner, Hartmut ;

Schlenk, Richard F. .

BLOOD, 2010, 116 (21) :901-902

[52] Eradication of minimal residual disease with alemtuzumab in chronic lymphocytic leukemia is associated with prolonged survival and is an appropriate theraputic endpoint for relapsed CLL [J].

Sayala, Hazem ;

Moreton, Paul ;

Kennedy, Ben ;

Lucas, Guy ;

Leach, Michael ;

Rassam, Saad M. B. ;

Haynes, Andrew ;

Tighe, Jane ;

Oscier, David G. ;

Fegan, Christopher ;

Rawstron, Andy C. ;

Hillmen, Peter .

BLOOD, 2007, 110 (11) :916A-916A

[53] Allogeneic Hematopoietic Stem-Cell Transplantation for Chronic Lymphocytic Leukemia With 17p Deletion: A Retrospective European Group for Blood and Marrow Transplantation Analysis [J].

Schetelig, Johannes ;

van Biezen, Anja ;

Brand, Ronald ;

Caballero, Dolores ;

Martino, Rodrigo ;

Itala, Maija ;

Garcia-Marco, Jose A. ;

Volin, Liisa ;

Schmitz, Norbert ;

Schwerdtfeger, Rainer ;

Ganser, Arnold ;

Onida, Francesco ;

Mohr, Brigitte ;

Stilgenbauer, Stephan ;

Bornhaeuser, Martin ;

de Witte, Theo ;

Dreger, Peter .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (31) :5094-5100

[54] Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics [J].

Sher, Taimur ;

Miller, Kena C. ;

Lawrence, David ;

Whitworth, Amy ;

Hernandez-Ilizaliturri, Francisco ;

Czuczman, Myron S. ;

Miller, Austin ;

Lawrence, William ;

Bilgram, Syed Ali ;

Sood, Raman ;

Wood, Margaret T. ;

Block, Annemarie W. ;

Lee, Kelvin ;

Chanan-Khan, Asher Alban .

LEUKEMIA & LYMPHOMA, 2010, 51 (01) :85-88

[55] Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning [J].

Sorror, Mohamed L. ;

Storer, Barry E. ;

Sandmaier, Brenda M. ;

Maris, Michael ;

Shizuru, Judith ;

Maziarz, Richard ;

Agura, Edward ;

Chauncey, Thomas R. ;

Pulsipher, Michael A. ;

McSweeney, Peter A. ;

Wade, James C. ;

Bruno, Benedetto ;

Langston, Amelia ;

Radich, Jerald ;

Niederwieser, Dietger ;

Blume, Karl G. ;

Storb, Rainer ;

Maloney, David G. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (30) :4912-4920

[56] Understanding and Managing Ultra High-Risk Chronic Lymphocytic Leukemia [J].

Stilgenbauer, Stephan ;

Zenz, Thorsten .

HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2010, :481-488

[57] Subcutaneous Alemtuzumab in Fludarabine-Refractory Chronic Lymphocytic Leukemia: Clinical Results and Prognostic Marker Analyses From the CLL2H Study of the German Chronic Lymphocytic Leukemia Study Group [J].

Stilgenbauer, Stephan ;

Zenz, Thorsten ;

Winkler, Dirk ;

Buehler, Andreas ;

Schlenk, Richard F. ;

Groner, Silja ;

Busch, Raymonde ;

Hensel, Manfred ;

Duehrsen, Ulrich ;

Finke, Juergen ;

Dreger, Peter ;

Jaeger, Ulrich ;

Lengfelder, Eva ;

Hohloch, Karin ;

Soeling, Ulrike ;

Schlag, Rudolf ;

Kneba, Michael ;

Hallek, Michael ;

Doehner, Hartmut .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (24) :3994-4001

[58] The natural history of fludarabine-refractory chronic lymphocytic leukemia patients who fail alemtuzumab or have bulky lymphadenopathy [J].

Tam, Constantine S. ;

O'Brien, Susan ;

Lerner, Susan ;

Khouri, I. ;

Ferrajoli, A. ;

Faderl, S. ;

Browning, M. ;

Tsimberidou, Apostolia M. ;

Kantarjian, Hagop ;

Wierda, William G. .

LEUKEMIA & LYMPHOMA, 2007, 48 (10) :1931-1939

[59] Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia [J].

Tsimberidou, Apostolia M. ;

Wierda, William G. ;

Plunkett, William ;

Kurzrock, Razelle ;

O'Brien, Susan ;

Wen, Sijin ;

Ferrajoli, Alessandra ;

Ravandi-Kashani, Farhad ;

Garcia-Manero, Guillermo ;

Estrov, Zeev ;

Kipps, Thomas J. ;

Brown, Jennifer R. ;

Fiorentino, Albert ;

Lerner, Susan ;

Kantarjian, Hagop M. ;

Keating, Michael J. .

JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (02) :196-203

[60]

Varghese AM, 2010, BLOOD, V116, P922

← 1 2 3 4 5 6 7 →